23andMe seeks second auction as ex-CEO outbids Regeneron
Source: SeekingAlpha
2025-06-05 07:13:35 ET
More on 23andMe, Regeneron Pharmaceuticals
- Itepekimab Failure A Setback For Sanofi And Regeneron
- Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
- Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
- Regeneron reports early data in mid-stage trial of obesity treatment
- Notable analyst calls this week: Southwest Airlines, Regeneron and Nvidia among top picks
Read the full article on Seeking Alpha
For further details see:
23andMe seeks second auction as ex-CEO outbids Regeneron
23andMe Holding
NASDAQ: MEHCQ
MEHCQ Trading
-5.93% G/L:
$3.53 Last:
39,176 Volume:
$3.45 Open:
MEHCQ Latest News
July 14, 2025 10:10:26 am
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets
June 30, 2025 08:00:05 am
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
June 13, 2025 04:22:32 pm
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
May 27, 2025 12:45:34 pm
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
MEHCQ Stock Data
$96,599,440
24,610,317
0.31%
19
N/A
Diversified Financial Services
Finance
US
San Francisco
